|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest a role of the IL-17/IL-23 cytokine axis in synovial LN in PsA.
|
22541888 |
2012 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent observations described and discussed in this review raise the clinically significant possibility of redefining the immunological role of IL-17 in PsA and provide a basis for defining future studies to elucidate the molecular and cellular functions of Act1.
|
23116200 |
2012 |
|
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population.
|
22955875 |
2013 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Newer drugs in the treatment armamentarium that have shown efficacy for both psoriasis and psoriatic arthritis consist of the anti-IL-17 agent, secukinumab, and a phosphodiesterase-4 inhibitor, apremilast.
|
23580094 |
2013 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Initially, it was thought that psoriasis and PsA were Th1-mediated diseases; however, studies in knockout animal models (IL-17 knockout mice) as well as human experimental data indicate that Th17 and its signature cytokine IL-17 have a critical role in the pathogenesis of psoriatic disease.
|
22362575 |
2013 |
|
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine whether the variation at the IL17 pathway genes was linked to the risk for PsO or had an effect on disease severity and the risk for Psoriatic arthritis (PsA).
|
26347322 |
2015 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review outlines the IL-17 pathway, summarises the evidence supporting its role in PsO and PsA and discusses recent data that may help to address these yet unresolved questions.
|
26209291 |
2015 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
CBP30 also inhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.
|
26261308 |
2015 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.
|
25512250 |
2015 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel therapeutics targeting these mediators (IL-12, IL-23, IL-17, IL-17 receptor, TNF) are effective in treating both the skin and joint manifestations of psoriasis, reaffirming the shared pathophysiology of PsV and PsA.
|
26780035 |
2016 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biological DMARDs (bDMARDs) targeting cytokines IL-12/IL-23, TNF and IL-17 involved in the pathogenesis of PsA, have been emerging for the treatment.
|
27586804 |
2016 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report the efficacy and safety of ixekizumab, a monoclonal antibody that selectively targets interleukin-17A, in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor inhibitors.
|
28551073 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert Commentary: The aim of this paper is to review the role of IL-17 in the pathogenesis and treatment of PsA, with a discussion on the emerging anti-IL-17 drugs for PsA.
|
28485176 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The significant enrichment of circulating IL-17 producing CD8+ T-cells in RA when compared to PsA warrants functional characterization and confirmation in larger studies.
|
29228429 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a preliminary study on psoriasis and PsA we showed that at 6 months apremilast decreased IFNγ+CD3+ Th1 cells and IL- 17+CD3+ Th17 cells and increased regulatory B cells and regulatory T cells.
|
28554321 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secukinumab, a human monoclonal antibody selectively neutralizing interleukin-17A, has demonstrated good efficacy and safety in the treatment of moderate-to-severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response.
|
28602039 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, IL-10+Breg cells are decreased PsA and Ps and inversely correlated with the severity of psoriasis and IL-17A+ and IFNγ+ T cells.
|
28461105 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subsequently, similar positive efficacy for inhibition of IL-17A was seen in patients with ankylosing spondylitis and psoriatic arthritis.
|
28270233 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
|
29283375 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
More specifically, increased knowledge of innate immunity and the important involvement of cytokines in the interleukin (IL)-23-IL-17 axis as key mediators of psoriatic plaque and joint inflammation in both psoriasis and PsA have led to new theories of immunopathogenesis.
|
28461524 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: Relevant references regarding the role of the IL-23/IL-17 pathway in the pathogenesis of psoriasis/psoriatic arthritis and clinical trials with IL-23p40 and IL-23p19 blocking agents were obtained through a literature search in MEDLINE/Pubmed for articles published until November 2016.
|
28165883 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis.
|
28633806 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active psoriatic arthritis (PsA).
|
27553214 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the 2-year efficacy and safety of the interleukin-17A inhibitor, secukinumab, in active psoriatic arthritis (PsA).
|
27696786 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/IL-17 axis plays a critical pathogenic role for both PsA and Ps, and biologics neutralizing IL-17A or IL-23/IL-12 are effective therapies for PsA and Ps.
|
27666819 |
2017 |